As of November 6, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of Stoke Therapeutics Inc. The largest reported stake is RTW Investments, LP's, at 9.9%. 23 filings are on record since July 15, 2025 (Schedule 13G/A, May 15, 2026).
Sell to companies like Stoke Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 4,819,851 · Shared voting: 0 · Sole dispositive: 4,820,462 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Reporting person: Biotechnology Value Fund L P · Sole voting: 0 · Shared voting: 1,866,761 · Sole dispositive: 0 · Shared dispositive: 1,866,761 · SCHEDULE 13G, 2026-09-30
- · Reporting person: Lynx1 Capital Management LP · Sole voting: 0 · Shared voting: 4,038,404 · Sole dispositive: 0 · Shared dispositive: 4,038,404 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: The Toronto-Dominion Bank · Sole voting: 3,173,258 · Shared voting: 0 · Sole dispositive: 3,173,258 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-12
- · Holder: Fmr LLC · Percent: 8.5% · SCHEDULE 13G/A
Stoke Therapeutics Inc has 23 Schedule 13D or 13G filings on record since 2025-07-15. 8 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| RTW Investments, LP | 9.9% | 5,940,866 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Fmr LLC | 7.5% | 4,820,462 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| BlackRock, Inc. | 6.8% | 3,732,540 | SCHEDULE 13G/A, 2025-10-17 | 2025-09-30 |
| Redmile Group, LLC | 6.7% | 4,164,120 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Lynx1 Capital Management LP | 6.5% | 4,038,404 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Baker Bros. Advisors LP | 5.8% | 3,336,697 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Bvf Partners L P | 5.6% | 3,608,968 | SCHEDULE 13G, 2026-09-30 | 2026-09-23 |
| Wellington Management Group LLP | 5.2% | 3,095,700 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| The Toronto-Dominion Bank | 4.9% | 3,173,258 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| BlackRock Portfolio Management LLC | 4.7% | 2,550,341 | SCHEDULE 13G/A, 2025-07-15 | 2025-06-30 |
| Skorpios Trust | 4.1% | 2,256,181 | SCHEDULE 13D/A, 2025-08-26 | 2025-08-22 |
| Cowen Financial Products LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Stoke Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Stoke Therapeutics Inc and the records around it.
Stoke Therapeutics Inc elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- Cowen Financial Products LLC also filed stake reports on 1 other company: UroGen Pharma Ltd. (Nov 2025)
- The Toronto-Dominion Bank also filed stake reports on 5 other companies: eBay Inc. (Aug 2026), UroGen Pharma Ltd. (Aug 2026), Immatics N.V. (May 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
Watch Stoke Therapeutics Inc
Get an email when Stoke Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Stoke Therapeutics Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Stoke Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Stoke Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
25 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 4,819,851 | 0 | 4,820,462 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 4,820,462 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Lynx1 Capital Management LP | 0 | 4,038,404 | 0 | 4,038,404 | SCHEDULE 13G/A, 2026-08-14 |
| Weston Nichols | 0 | 4,038,404 | 0 | 4,038,404 | SCHEDULE 13G/A, 2026-08-14 |
| Biotechnology Value Fund L P | 0 | 1,866,761 | 0 | 1,866,761 | SCHEDULE 13G, 2026-09-30 |
| Bvf I Gp LLC | 0 | 1,866,761 | 0 | 1,866,761 | SCHEDULE 13G, 2026-09-30 |
| Biotechnology Value Fund Ii LP | 0 | 1,404,263 | 0 | 1,404,263 | SCHEDULE 13G, 2026-09-30 |
| Bvf Ii Gp LLC | 0 | 1,404,263 | 0 | 1,404,263 | SCHEDULE 13G, 2026-09-30 |
| Biotechnology Value Trading Fund OS LP | 0 | 261,006 | 0 | 261,006 | SCHEDULE 13G, 2026-09-30 |
| BVF Partners OS Ltd. | 0 | 261,006 | 0 | 261,006 | SCHEDULE 13G, 2026-09-30 |
| Bvf Gp Holdings LLC | 0 | 3,271,024 | 0 | 3,271,024 | SCHEDULE 13G, 2026-09-30 |
| Bvf Partners L P | 0 | 3,608,968 | 0 | 3,608,968 | SCHEDULE 13G, 2026-09-30 |
| Bvf Inc | 0 | 3,608,968 | 0 | 3,608,968 | SCHEDULE 13G, 2026-09-30 |
| Lampert Mark N | 0 | 3,608,968 | 0 | 3,608,968 | SCHEDULE 13G, 2026-09-30 |
| The Toronto-Dominion Bank | 3,173,258 | 0 | 3,173,258 | 0 | SCHEDULE 13G/A, 2026-08-12 |
| TD Securities Inc. | 10,000 | 0 | 10,000 | 0 | SCHEDULE 13G/A, 2026-08-12 |
The latest filing identifies Stoke Therapeutics Inc by CUSIP 86150R107 and gives its principal executive office as 45 WIGGINS AVENUE, BEDFORD, MA 01730 (SCHEDULE 13G/A, 2026-11-05).
What the percentages are based on
The following percentages are based on 64,526,242 Shares outstanding as of July 30, 2026, which is the total number of Shares outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 3, 2026.Bvf Partners L P, SCHEDULE 13G, 2026-09-30
Purpose of Transaction (Item 4)
Skorpios Trust
Item 4 is hereby amended and supplemented by adding the following: On August 22, 2025, Blue Horizon sold 1,000,000 Shares of the Issuer in an open market transaction at a price of $18.50 per share.Item 4 of the SCHEDULE 13D/A filed 2025-08-26
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-15 | BlackRock Portfolio Management LLC | 4.7% | SCHEDULE 13G/A |
| 2025-07-29 | Cowen Financial Products LLC | 5.8% | SCHEDULE 13G/A |
| 2025-08-06 | Fmr LLC | 13.6% | SCHEDULE 13G/A |
| 2025-08-14 | Redmile Group, LLC | 8% | SCHEDULE 13G/A |
| 2025-08-26 | Skorpios Trust | 4.1% | SCHEDULE 13D/A |
| 2025-10-17 | BlackRock, Inc. | 6.8% | SCHEDULE 13G/A |
| 2025-11-05 | Fmr LLC | 12.5% | SCHEDULE 13G/A |
| 2025-11-14 | The Toronto-Dominion Bank | 5.8% | SCHEDULE 13G |
| 2025-11-14 | Cowen Financial Products LLC | 0% | SCHEDULE 13G/A |
| 2026-02-05 | Fmr LLC | 9.8% | SCHEDULE 13G/A |
| 2026-02-17 | Baker Bros. Advisors LP | 5.8% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-15 | Wellington Management Group LLP | 5.2% | SCHEDULE 13G |
| 2026-05-15 | Lynx1 Capital Management LP | 7% | SCHEDULE 13G/A |
| 2026-05-15 | The Toronto-Dominion Bank | 5.4% | SCHEDULE 13G/A |
| 2026-05-15 | Redmile Group, LLC | 6.7% | SCHEDULE 13G/A |
| 2026-05-15 | RTW Investments, LP | 9.9% | SCHEDULE 13G/A |
| 2026-05-18 | Lynx1 Capital Management LP | 8.1% | SCHEDULE 13G/A |
| 2026-08-06 | Fmr LLC | 8.5% | SCHEDULE 13G/A |
| 2026-08-12 | The Toronto-Dominion Bank | 4.9% | SCHEDULE 13G/A |
| 2026-08-14 | Lynx1 Capital Management LP | 6.5% | SCHEDULE 13G/A |
| 2026-09-30 | Bvf Partners L P | 5.6% | SCHEDULE 13G |
| 2026-11-05 | Fmr LLC | 7.5% | SCHEDULE 13G/A |
Questions about who owns Stoke Therapeutics Inc
Who owns Stoke Therapeutics Inc?
On this page, 8 holders' latest ownership filings report 5% or more of Stoke Therapeutics Inc: RTW Investments, LP (9.9%, Schedule 13G/A, filed 2026-05-15), Fmr LLC (7.5%, Schedule 13G/A, filed 2026-11-05), BlackRock, Inc. (6.8%, Schedule 13G/A, filed 2025-10-17), Redmile Group, LLC (6.7%, Schedule 13G/A, filed 2026-05-15) and Lynx1 Capital Management LP (6.5%, Schedule 13G/A, filed 2026-08-14); 3 more are listed above.
Who are the largest shareholders of Stoke Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Stoke Therapeutics Inc on this page are RTW Investments, LP (9.9%), Fmr LLC (7.5%) and BlackRock, Inc. (6.8%).
When did RTW Investments, LP buy into Stoke Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from RTW Investments, LP on this page is the Schedule 13G/A, filed 2026-05-15, reporting 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 23 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Stoke Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 25, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| April 7, 2026 | Leadership change: G. Clare Kahn appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Stoke Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.